Moreover, HER2-interacting partners, such as junctional adhesion molecule-A (JAM-A), which regulates HER2 expression, have been identified as overexpressed in aggressive DCIS lesions, in correlation with angiogenetic and apoptotic pathway alterations [56]. Here, ERBB2 is linked to ductal breast carcinoma in situ.